ReviewBreast cancer (Dove Medical Press)2025
Advancements in Dalpiciclib for the Treatment of Breast Cancer Patients: A Review.
Review in Breast cancer (Dove Medical Press), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Efficacy and safety of dalpiciclib combined with endocrine therapy in elderly patients with HRFrontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Combining cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6 inhibitors) with cyclin-dependent proteins can reduce the formation of cyclin D-CDK4/6 complexes, resulting in the inactivation of downstream genes and suppression of cell proliferation. Previous research on the use of CDK4/6 inhibitors in combination with endocrine therapies and anti-HER2 targeting agents across various subtypes and stages of breast cancer has shown promising outcomes in patient prognoses and tolerable drugs toxicities. For the present, the CDK4/6 inhibitors that have been widely used for the treatment of breast cancer are palbociclib, abemaciclib and ribociclib. Dalpiciclib (SHR6390), a novel and selective CDK4/6 inhibitor developed in China, has been approved by the National Medical Products Administration. The researches about dalpiciclib with different anti-tumor drugs are ongoing to explore the efficacy and the best strategies to use dalpiciclib. This review provides an overview of the research progress on dalpiciclib across different breast cancer subtypes with various anti-tumor drugs in different treatment opportunities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.